Issue: May 2015
April 20, 2015
1 min read
Save

Trial Scorecard: OSLER

Issue: May 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Investigators conducted two extension studies of the effect of evolocumab on the lowering of LDL levels.

Trial Scorecard: OSLER